Core Insights - H. Lundbeck A/S is showcasing its leadership in migraine management with new data on eptinezumab at the 2025 International Headache Congress, emphasizing the drug's long-term effectiveness and safety in chronic migraine patients [1][2][3] Group 1: Clinical Trials and Results - The RESOLUTION trial demonstrated that approximately 50% of patients achieved a ≥50% reduction in monthly migraine days (MMDs) after 12 weeks of treatment with eptinezumab, with a baseline of 20.9 MMDs [1][9][10] - The SUNSET trial, an extension of the SUNRISE trial, showed that 35.7% of Japanese patients achieved a ≥50% reduction in MMDs by weeks 49-60, with a trend towards increased response rates over the 60-week period [1][12][13] - Eptinezumab was well tolerated in both trials, aligning with previous studies on migraine prevention [1][2] Group 2: Presentations at the International Headache Congress - Lundbeck will present six studies at the 2025 International Headache Congress, including three oral presentations on eptinezumab and Lu AG09222 [2][4] - Key presentations include the efficacy and safety of eptinezumab in chronic migraine and medication-overuse headache, as well as patient-reported outcomes in a predominantly Asian population [4][5] Group 3: Migraine Impact and Management - Migraine is a leading cause of years lived with disability, affecting nearly 50 million people in Europe and costing the economy EUR 18 billion annually [6][10] - The chronic nature of migraine and associated medication overuse headache can lead to increased disability and a cycle of worsening symptoms without proper management [7][8]